title: [Neoadjuvant intra-arterial infusion chemotherapy in over stage III and inflammatory carcinoma of the breast].
abstract: From 1991 to 1996, 11 eligible patients (median age 50.4 years, range 33-71 years) with over Stage III and inflammatory breast carcinoma have been treated with neoadjuvant intra-arterial infusion chemotherapy. There were three Stage III a, one III b, three IV and four inflammatory carcinoma. Patients were treated with Epirubicin (10) and Doxorubicin (1), with a total amount of 120-190 mg. Three cases were combined with endocrine therapy (MPA 1,200 mg). In terms of morphological efficacy, 10 of 11 achieved PR, and three of those with endocrine therapy had over Grade 2 in histological efficacy. Carcinoma cells were especially deceased in one inflammatory carcinoma with MPA. Three of 11 died of liver metastasis, the others are still alive (median 24.5 months, range 7-51 months). Combined endocrine therapy should be considered applicable for the treatment strategy of the breast carcinoma.
authors.affiliation: First Dept. of Surgery, Nippon Medical School.
authors.forename: K
authors.initials: K
authors.lastname: Higuchi
authors.forename: M
authors.initials: M
authors.lastname: Onda
authors.forename: K
authors.initials: K
authors.lastname: Furukawa
authors.forename: K
authors.initials: K
authors.lastname: Minobe
authors.forename: N
authors.initials: N
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Arima
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D015251:Epirubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008413:Mastitis / Q000473:pathology; D008525:Medroxyprogesterone / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging
chemical_list: D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D008525:Medroxyprogesterone